Which of the patient’s current medications (bupropion XL 300 mg, escitalopram 10 mg, allopurinol 100 mg, ibuprofen 400 mg twice daily, amlodipine 5 mg, atenolol 25 mg, valsartan 80 mg, ezetimibe 10 mg, famotidine 20 mg, zolpidem 10 mg, folic acid 400 µg, vaginal estrogen 10 µg twice weekly, probiotic) could be causing a 10‑day facial erythema, peeling, and pruritus?

Allopurinol is the Most Likely Culprit for This Patient's Facial Rash

Allopurinol should be discontinued immediately, as the FDA label explicitly states: "ALLOPURINOL TABLETS SHOULD BE DISCONTINUED AT THE FIRST APPEARANCE OF SKIN RASH OR OTHER SIGNS WHICH MAY INDICATE AN ALLERGIC REACTION." 1 This 10-day facial erythema with peeling and pruritus represents a potentially serious cutaneous adverse drug reaction that can progress to life-threatening conditions including Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS syndrome. 1

Why Allopurinol is the Primary Suspect

Allopurinol is the single most common cause of severe cutaneous adverse drug reactions worldwide, accounting for 10.7% of all cutaneous ADRs in one large observational study. 2 The clinical presentation of facial red, peeling, and pruritic skin at 10 days is consistent with the typical 2-6 week latency period for allopurinol-induced reactions. 3

Key Risk Factors Present in This Patient

• The patient is on multiple medications that suggest advanced age and comorbidities (atenolol, amlodipine, valsartan suggest cardiovascular disease; ezetimibe suggests dyslipidemia), and advanced age is a major risk factor for allopurinol-induced severe cutaneous reactions. 2

• No mention of dose adjustment for renal function, which is critical because renal impairment significantly increases the risk and severity of allopurinol-induced SCARs. 1, 4

• Allopurinol is frequently prescribed inappropriately for asymptomatic hyperuricemia (95% of cases in one study), increasing unnecessary exposure to this high-risk medication. 2

Other Medications with Lower Probability

Bupropion (Wellbutrin XL 300 mg)

• Can cause cutaneous reactions but is far less commonly associated with severe facial dermatitis compared to allopurinol
• No specific FDA warnings about discontinuation at first sign of rash

Escitalopram (Lexapro 10 mg)

• Rarely associated with significant cutaneous reactions
• Not a common cause of facial peeling dermatitis

Ibuprofen (Advil 400 mg BID)

• NSAIDs can cause cutaneous reactions, but the pattern described (localized facial involvement with peeling) is less typical
• Would more commonly present as generalized maculopapular eruption or urticaria

Amlodipine (5 mg)

• Calcium channel blockers can rarely cause photosensitivity reactions
• Not typically associated with facial peeling and pruritus without sun exposure

Other Medications (Atenolol, Valsartan, Ezetimibe, Famotidine, Zolpidem, Folic Acid, Vagifem, Probiotics)

• These have minimal to no association with the described cutaneous reaction pattern

Immediate Management Algorithm

Step 1: Discontinue Allopurinol Immediately

Stop allopurinol at once without waiting for further diagnostic confirmation. 1 The FDA label is unequivocal about this requirement, and delay can result in progression to fatal conditions. 1, 5

Step 2: Assess for Systemic Involvement

• Check for fever, mucosal involvement, conjunctival lesions, or blistering, which would indicate progression to SJS/TEN or DRESS syndrome. 5, 3
• Obtain complete blood count with differential to evaluate for eosinophilia (DRESS syndrome). 3
• Check liver function tests and renal function, as allopurinol can cause hepatotoxicity and reactions are more severe with renal impairment. 1, 4

Step 3: Initiate Symptomatic Treatment

For localized facial involvement without systemic symptoms:

• Apply moderate-to-high potency topical corticosteroid (mometasone furoate 0.1% or betamethasone valerate 0.1% ointment) twice daily to affected areas. 6
• Prescribe aggressive emollient therapy to prevent xerosis-related worsening. 6
• Add oral antihistamine: loratadine 10 mg daily for daytime (non-sedating) and hydroxyzine 25-50 mg at bedtime if sleep is disrupted. 6, 7

Reassess after 2 weeks; if worsening or no improvement, escalate therapy. 6

Step 4: Escalation for Moderate-to-Severe or Progressive Symptoms

• If the rash extends beyond the face, develops blistering, or involves mucous membranes, transfer immediately to a facility with ICU and dermatology expertise. 5
• Consider systemic corticosteroids (prednisolone) for progressive reactions, though evidence is mixed. 4, 5
• For refractory pruritus, add gabapentin 900-3600 mg daily (titrated from low dose) or pregabalin 25-150 mg daily. 6

Critical Pitfalls to Avoid

• Do not continue allopurinol "to see if it gets better"—the FDA label mandates immediate discontinuation, and continued exposure can be fatal. 1

• Do not assume this is a benign rash—52% of allopurinol-related cutaneous ADRs are serious, with 32% mortality in SJS/TEN cases. 8, 2

• Do not overlook renal function—failure to adjust allopurinol dose for creatinine clearance is a major contributor to severe reactions. 1, 2

• Do not delay hospitalization if systemic symptoms develop—fever, mucosal involvement, or skin detachment require immediate ICU-level care. 5

• Do not restart allopurinol after resolution—this is a definitive contraindication, and rechallenge can be fatal. 1

Documentation and Follow-Up

• Document this as a definite adverse drug reaction to allopurinol in the patient's medical record and allergy list. 2
• Report to pharmacovigilance authorities, as allopurinol reactions are serious and underreported. 8
• Monitor for complete resolution over 4-6 weeks, as some reactions (particularly DRESS) can have prolonged courses. 3
• If hyperuricemia treatment is still needed, consider febuxostat as an alternative, but only after complete resolution and with careful monitoring. 2